Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | MIF | P14174 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799512 | 0.87 | METAP1 (0.41) | CES2MIFMAOAMAOB | |
| SCHEMBL6795161 | 0.84 | ESR1 (0.37) | CES2ESR2ESR1MAOAMAOB | |
| SCHEMBL6801815 | 0.76 | ESR2 (0.41) | ESR2ESR1MAOAMAOB | |
| SCHEMBL6800106 | 0.76 | MAOA (0.47) | CES2ESR2ESR1MIFMAPT | |
| SCHEMBL6806691 | 0.76 | ESR2 (0.46) | ESR2ESR1MAOAMAOB | |
| SCHEMBL6795670 | 0.75 | CES2 (0.45) | CES2ESR2ESR1MIFALDH1A1 | |
| SCHEMBL6794340 | 0.73 | METAP1 (0.42) | CES2MIFALDH1A1MAPTMAOB | |
| SCHEMBL6794708 | 0.73 | PBRM1 (0.46) | CES2ESR2ESR1MAPTMAOA | |
| SCHEMBL6796152 | 0.70 | SMN1; SMN2 (0.53) | CES2ESR2ESR1MIFMAOA | |
| SCHEMBL6794474 | 0.69 | ESR2 (0.45) | ESR2ESR1MIFALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | CES2 3694/4885ESR2 5/4885ESR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.